Senti Biosciences' (SNTI) Buy Rating Reaffirmed at Chardan Capital

Senti Biosciences (NASDAQ:SNTI - Get Free Report)'s stock had its "buy" rating restated by investment analysts at Chardan Capital in a report released on Thursday,Benzinga reports. They currently have a $12.00 price objective on the stock. Chardan Capital's price objective suggests a potential upside of 361.54% from the stock's current price.

Separately, Laidlaw started coverage on shares of Senti Biosciences in a research report on Friday, June 6th. They set a "buy" rating and a $5.00 target price on the stock.

Senti Biosciences Price Performance

Senti Biosciences stock traded down $0.26 during midday trading on Thursday, hitting $2.60. The company's stock had a trading volume of 94,636 shares, compared to its average volume of 809,089. Senti Biosciences has a 1-year low of $1.52 and a 1-year high of $16.94. The company has a 50-day moving average price of $3.37 and a two-hundred day moving average price of $3.86. The company has a market cap of $67.81 million, a price-to-earnings ratio of -0.17 and a beta of 2.23.

Senti Biosciences (NASDAQ:SNTI - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.85). The firm had revenue of $1.30 million for the quarter, compared to the consensus estimate of $1.30 million. Sell-side analysts forecast that Senti Biosciences will post -14.54 EPS for the current year.

Institutional Trading of Senti Biosciences

Several large investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC bought a new stake in shares of Senti Biosciences during the 4th quarter valued at $47,000. Renaissance Technologies LLC bought a new stake in shares of Senti Biosciences during the 4th quarter valued at $181,000. Heights Capital Management Inc. bought a new stake in shares of Senti Biosciences during the 1st quarter valued at $2,520,000. Finally, Nantahala Capital Management LLC bought a new stake in shares of Senti Biosciences during the 1st quarter valued at $2,984,000. Institutional investors own 25.73% of the company's stock.

Senti Biosciences Company Profile

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.